反応式
Cl[C:2]1[N:7]=[C:6]([NH:8][C:9]2[CH:17]=[CH:16][CH:15]=[C:14]3[C:10]=2[CH:11]=[CH:12][N:13]3[CH3:18])[C:5]([C:19]([OH:21])=O)=[CH:4][N:3]=1.[CH:22]1[CH:23]=[CH:24][C:25]2[N:30]([OH:31])[N:29]=[N:28][C:26]=2[CH:27]=1.C(Cl)CCl.[NH3:36]>CN(C=O)C.CCOC(C)=O.O>[N:30]1([O:31][C:2]2[N:7]=[C:6]([NH:8][C:9]3[CH:17]=[CH:16][CH:15]=[C:14]4[C:10]=3[CH:11]=[CH:12][N:13]4[CH3:18])[C:5]([C:19]([NH2:36])=[O:21])=[CH:4][N:3]=2)[C:25]2[CH:24]=[CH:23][CH:22]=[CH:27][C:26]=2[N:28]=[N:29]1参加物
8
反応物 4
生成物 1
試薬・触媒・溶媒 3
実験手順
To a solution of 2-chloro-4-(1-methyl-1H-indol-4-ylamino)pyrimidine-5-carboxylic acid (325 mg, 1.08 mmol) and HOBt (198 mg, 1.29 mmol) in DMF (4 mL), EDC (248 mg, 1.29 mmol) was added. The mixture was stirred at room temperature for 1.5 h. Ammonia (0.5 M in dioxane, 8.00 mL, and 4.00 mmol) was added. It was stirred at room temperature overnight. Water and EtOAc were added. The organic phase was separated, washed with 1 N HCl, then with 5% NaHCO3, dried over Na2SO4, concentrated in vacuo to give 2-(1H-benzo[d][1,2,3]triazol-1-yloxy)-4-(1-methyl-1H-indol-4-ylamino)pyrimidine-5-carboxamide (378 mg). MS 401.4 (M+H)
後処理
- stirringIt was stirred at room temperature overnight
- customThe organic phase was separated
- washwashed with 1 N HCl
- dry with materialwith 5% NaHCO3, dried over Na2SO4
- concentrationconcentrated in vacuo
出典と根拠
- ORDレコード
- ord-742b04e1009644309b510c14c1dac161
- 出典データセット
- uspto-grants-2013_01
- 特許番号
- US08349860B2
関連ノート
読み込み中…